PhaseBio Pharmaceuticals, Inc.
4020 Aerial Center Parkway
83 articles with PhaseBio Pharmaceuticals, Inc.
Ticagrelor is unique among P2Y12 antagonist antiplatelet agents due to its ability to reversibly bind to the receptor, whereas other P2Y12 antagonists bind permanently.
PhaseBio Receives FDA Orphan Drug Designation For Vasomera (PB1046) For The Treatment Of Cardiomyopathy Associated With Dystrophinopathies
PhaseBio Announces Initiation Of Phase IIa Multiple Ascending Dose Study Of Once-Weekly Basal Insulin PE0139 In Type 2 Diabetes
PhaseBio Announces Promising Pre-Clinical Results For PB1046 In Models Of Duchenne Muscular Dystrophy
PhaseBio Pharmaceuticals, Inc. Expands Clinical Development of Vasomera, an Investigational Treatment for Cardiopulmonary Diseases
PhaseBio Pharmaceuticals, Inc. Initiated Phase 1 Study of Investigational Once-Weekly Basal Insulin for Potential Treatment of Diabetes
PhaseBio Pharmaceuticals, Inc. to Present at the Jefferies and Co. 2013 Global Healthcare Conference
PhaseBio Pharmaceuticals, Inc. Positions for the Next Stage of Development by Bringing on Board Industry Veteran, Jonathan Mow as Chief Business Officer
PhaseBio Pharmaceuticals, Inc. Initiates a Multicenter, Randomized Placebo and Active Comparator Controlled Phase 2b Trial to Evaluate Use of Glymera for the Treatment of Uncontrolled Type 2 Diabetes
PhaseBio Pharmaceuticals, Inc. Received an Additional $23 Million With Completion of the Third Tranche of a Series B Financing for Advancement of Metabolic and Cardiovascular Product Portfolio
PhaseBio Pharmaceuticals, Inc. Launches Clinical Program to Evaluate Novel VPAC2 Agonist for Cardiovascular Disease
PhaseBio Pharmaceuticals, Inc. Announces Positive Clinical Results with its Once Weekly GLP-1 analogue, Glymera™ for the Treatment of Hyperglycemia in Patients with Type 2 Diabetes
PhaseBio Pharmaceuticals, Inc. Announces the Appointment of Kathryn J. Gregory Vice President of Business Development
PhaseBio Pharmaceuticals, Inc. Reaches Key Milestones and Receives $15 Million to Complete Series B Financing